CDK

Cyclin dependent kinase

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

(+)-Enitociclib

((+)-BAY-1251152; (+)-VIP152) Cat. No.: HY-103019

(+)-Enitociclib ((+)-BAY-1251152) is an enanthiomer of BAY-1251152 with rotation (+). (+)-Enitociclib is a potent and selective **CDK9** inhibitor with an IC_{50} of 3 nM. (+)-Enitociclib has anti-tumour activity.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

(-)-Enitociclib

((-)-BAY-1251152; (-)-VIP152) Cat. No.: HY-103019B

(-)-Enitociclib ((-)-BAY-1251152) is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective **PTEF/CDK9** inhibitor.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

(2S,3R)-Voruciclib

Cat. No.: HY-12422C

(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active **CDK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(2S,3R)-Voruciclib hydrochloride

Cat. No.: HY-12422B

(2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride. (2S,3R)-Voruciclib is an orally active **CDK** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-BIO-acetoxime

(GSK-3 Inhibitor X) Cat. No.: HY-114903

(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective **GSK-3α/β** inhibitor, with an IC_{50} of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over **CDK5/p25**, **CDK2/cyclin A** and **CDK1/cyclin B** (IC_{50}=2.4, 4.3, 63 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

(E/Z)-TG003

Cat. No.: HY-15338A

(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of **Clk1/Sty**; inhibits Clk1 and Clk4 with IC_{50} values of 20 and 15 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib

((E/Z)-TG02; (E/Z)-SB1317) Cat. No.: HY-15166

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3**. (E/Z)-Zotiraciclib ((E/Z)-TG02) can be used for the research of cancer.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib citrate

((E/Z)-TG02 citrate; (E/Z)-SB1317 citrate) Cat. No.: HY-15166B

(E/Z)-Zotiraciclib citrate is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib hydrochloride

((E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride) Cat. No.: HY-15166A

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(R)-CR8 trihydrochloride

(CR8, (R)-Isomer trihydrochloride) Cat. No.: HY-18340A

(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent **CDK1/2/5/7/9** inhibitor.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(R)-CR8

(CR8, (R)-Isomer)

Cat. No.: HY-18340

(R)-CR8 (CR8), a second-generation analog of Roscovitine, is a potent **CDK1/2/5/7/9** inhibitor.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

(S)-Cdc7-IN-18

Cat. No.: HY-143432A

(S)-Cdc7-IN-18 is a potent inhibitor of **CDC7**. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-CR8

Cat. No.: HY-112371

(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective **CDK** inhibitor with IC_{50}s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC_{50} 0.40μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(±)-Enitociclib

((±)-BAY-1251152; (±)-VIP152)

Cat. No.: HY-103019A

(±)-Enitociclib ((±)-BAY-1251152) is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective **PTEF/CDK9** inhibitor.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

2,4,6-Trihydroxybenzoic acid

Cat. No.: HY-W077292

2,4,6-Trihydroxybenzoic acid, the flavonoid metabolite, is a **CDK** inhibitor.
2,4,6-Trihydroxybenzoic acid can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 g

3-Methylthienyl-carbonyl-JNJ-7706621

Cat. No.: HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of **cyclin-dependent kinase (CDK)**, with IC_{50}s of 6.4 nM and 2 nM for **CDK1/cyclinB** and **CDK2/cyclinA**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3MB-PP1

Cat. No.: HY-102069

3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (**Plk1**) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,6-Dichlorobenzimidazole riboside

(DRB)

Cat. No.: HY-14392

5,6-Dichlorobenzimidazole riboside is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 25 mg

5-Iodo-indirubin-3'-monoxime

Cat. No.: HY-111930

5-Iodo-indirubin-3'-monoxime is a potent **GSK-3β**, **CDK5/P25** and **CDK1/cyclin B** inhibitor, competing with ATP for binding to the catalytic site of the kinase, with IC_{50}s of 9, 20 and 25 nM, respectively.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

6-(Dimethylamino)purine

(6-Dimethylaminopurine)

Cat. No.: HY-W010128

6-(Dimethylamino)purine is a dual inhibitor of **protein kinase** and **CDK**.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 250 mg

7BIO
(7-Bromoindirubin-3-Oxime) Cat. No.: HY-121035

7BIO (7-Bromoindirubin-3-Oxime) is the derivate of indirubin. 7BIO (7-Bromoindirubin-3-Oxime) has inhibitory effects against cyclin-dependent kinase-5 (**CDK5**) and glycogen synthase kinase-3β (**GSK3β**).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abemaciclib
(LY2835219) Cat. No.: HY-16297A

Abemaciclib (LY2835219) is a selective **CDK4/6** inhibitor with IC_{50} values of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Abemaciclib metabolite M18
(LSN3106729) Cat. No.: HY-126534

Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity. Abemaciclib metabolite M18 and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib metabolite M18 hydrochloride
(LSN3106729 hydrochloride) Cat. No.: HY-126534A

Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abemaciclib metabolite M18-d8
(LSN3106729-d8) Cat. No.: HY-126534S

Abemaciclib metabolite M18-d8 (LSN3106729-d8) is the deuterium labeled Abemaciclib metabolite M18. Abemaciclib metabolite M18 (LSN3106729), the metabolite of Abemaciclib (HY-16297A), is a **CDK** inhibitor with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib metabolite M2
(LSN2839567) Cat. No.: HY-128669

Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent **CDK4** and **CDK6** inhibitor, with IC_{50}s in the range of 1-3 nM. Anti-cancer activity.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Abemaciclib metabolite M2-d6
(LSN2839567-d6) Cat. No.: HY-128669S

Abemaciclib metabolite M2-d6 (LSN2839567-d6) is the deuterium labeled Abemaciclib metabolite M2. Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent **CDK4** and **CDK6** inhibitor, with IC_{50}s in the range of 1-3 nM. Anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib metabolite M20
(LSN3106726) Cat. No.: HY-129336

Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective **CDK4/6** inhibitor for the treatment of cancer.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Abemaciclib metabolite M20-d8
(LSN3106726-d8) Cat. No.: HY-129336S

Abemaciclib metabolite M20-d8 (LSN3106726-d8) is the deuterium labeled Abemaciclib metabolite M20. Abemaciclib metabolite M20 (LSN3106726), the active metabolite of Abemaciclib, is a selective CDK4/6 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib methanesulfonate
(LY2835219 methanesulfonate) Cat. No.: HY-16297

Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective **CDK4/6** inhibitor with IC_{50}s of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Abemaciclib-d7

(LY2835219-d7) Cat. No.: HY-16297AS1

Abemaciclib-d7 (LY2835219-d7) is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective **CDK4/6** inhibitor with IC_{50} values of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abemaciclib-d8

(LY2835219-d8) Cat. No.: HY-16297AS

Abemaciclib-d8 (LY2835219-d8) is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective **CDK4/6** inhibitor with IC_{50} values of 2 nM and 10 nM for CDK4 and CDK6, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

AG-494

(Tyrphostin AG 494) Cat. No.: HY-101042

AG-494 (Tyrphostin AG 494) is a potent and selective **EGFR** tyrosine kinase inhibitor (IC_{50}=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC_{50}s 1.1, 39, 45 and 6 μM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Aloisine A

(RP107) Cat. No.: HY-112363

Aloisine A (RP107) is a a potent cyclin-dependent kinase (CDK) inhibitor with IC_{50}s of 0.15 μM, 0.12 μM, 0.4 μM, 0.16 μM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK5/p35, respectively. Aloisine A ininhibits GSK-3α (IC_{50}=0.5 μM) and GSK-3β (IC_{50}=1.5 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alsterpaullone

(9-Nitropaullone; NSC 705701) Cat. No.: HY-108359

Alsterpaullone (9-Nitropaullone) is a potent **CDK** inhibitor, with IC_{50}s of 35 nM, 15 nM, 200 nM and 40 nM for **CDK1/cyclin B**, **CDK2/cyclin A**, **CDK2/cyclin E** and **CDK5/p35**, respectively.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AMG 925

Cat. No.: HY-15889

AMG 925 is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

AMG 925 HCl

Cat. No.: HY-15889A

AMG 925 HCl is a potent, selective, and orally available **FLT3/CDK4** dual inhibitor with IC_{50}s of 2±1 nM and 3±1 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Aminopurvalanol A

Cat. No.: HY-104013

Aminopurvalanol A is a potent, selective, and cell permeable inhibitor of **Cyclins/Cdk** complexes. Aminopurvalanol A preferentially targets the G2/M-phase transition inhibiting cancer cell differentiation.



Purity: 98.00%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Anticancer agent 29

Cat. No.: HY-115942

Anticancer agent 29 (Compd E/Z-6f) is an anticancer agent, with IC_{50} values of 0.054 μM, 0.127 μM, 0.129 μM, 0.396 μM for CDK2, CDK1, CDK4 and CDK6, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Anticancer agent 30

Cat. No.: HY-115943

Anticancer agent 30 (compound 6f-Z), a 3-arylidene-2-oxindole derivative, is a selective **CDK2** inhibitor with potent anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS-0141

(Cdc7-IN-6)

Cat. No.: HY-130518



AS-0141 (Cdc7-IN-6) is a potent **Cdc7** kinase inhibitor (IC_{50}=4 nM), extracted from patent WO2019165473A1, compound I- D, has anti-tumor activity.

Purity: 98.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS2863619

Cat. No.: HY-126675A



AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS2863619 free base

Cat. No.: HY-126675



AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.

Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7519

(AT7519M)

Cat. No.: HY-50940



AT7519 (AT7519M) as a potent inhibitor of **CDKs**, with IC_{50}s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7519 Hydrochloride

Cat. No.: HY-50943



AT7519 Hydrochloride is a potent inhibitor of **CDKs**, with IC_{50}s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

Purity: 99.29%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT7519 TFA

(AT7519M TFA)

Cat. No.: HY-50940A



AT7519 (AT7519M) TFA as a potent inhibitor of **CDKs**, with IC_{50}s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.

Purity: 98.53%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Atuveciclib

(BAY-1143572)

Cat. No.: HY-12871B



Atuveciclib (BAY-1143572) is a potent and highly selective, oral **PTEFb/CDK9** inhibitor. Atuveciclib (BAY-1143572) inhibits **CDK9/CycT1** with an IC_{50} of 13 nM.

Purity: 99.20%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Atuveciclib Racemate

(BAY-1143572 Racemate)

Cat. No.: HY-12871



Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral **P-TEFb/CDK9** inhibitor which supresses **CDK9/CycT1** with an IC_{50} of 13 nM.

Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Atuveciclib S-Enantiomer

(BAY-1143572 S-Enantiomer)

Cat. No.: HY-12871C



Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective **CDK9** inhibitor, which inhibits **CDK9/CycT1** with an IC_{50} of 16 nM.

Purity: 99.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

AUZ 454

(K03861)

Cat. No.: HY-15004



AUZ 454 (K03861) is a type II **CDK2** inhibitor with K_d of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Avotaciclib

(BEY1107) Cat. No.: HY-137432

Avotaciclib (BEY1107) is a potent and orally active inhibitor of **cyclin dependent kinase 1 (CDK1)**. Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Avotaciclib trihydrochloride

(BEY1107 trihydrochloride) Cat. No.: HY-137432A

Avotaciclib (BEY1107) trihydrochloride is a potent and orally active inhibitor of **cyclin dependent kinase 1 (CDK1)**. Avotaciclib trihydrochloride can be used for the research of locally advanced or metastatic pancreatic cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ5576

Cat. No.: HY-143584

AZ5576 is a potent and highly selective **CDK9** inhibitor. AZ5576 can be used for hematological Malignancy research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-5438

Cat. No.: HY-10012

AZD-5438 is a potent **CDK1**, **CDK2**, and **CDK9** inhibitor, with IC_{50}s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6 .



Purity: 99.55%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

AZD4573

Cat. No.: HY-112088

AZD4573 is a potent and highly selective **CDK9** inhibitor (IC_{50} of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies.



Purity: 99.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BGG463

(K03859) Cat. No.: HY-100600

BGG463 (K03859) is an orally active type II **CDK2** inhibitor.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-1347

Cat. No.: HY-120350

BI-1347 is a potent **CDK8** inhibitor extracted from patent WO2017202719A1, product I-003, has an IC_{50} of 1.1 nM.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

bio-THZ1

Cat. No.: HY-128867

bio-THZ1 is a biotinylated version of THZ1 and binds irreversibly to CDK7. THZ1 is a selective and potent covalent **CDK7** inhibitor with an IC_{50} of 3.2 nM.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bisindolylmaleimide X hydrochloride

(BIM-X hydrochloride; Ro31-8425 hydrochloride) Cat. No.: HY-108136A

Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective **protein kinase C (PKC)** inhibitor. Bisindolylmaleimide X hydrochloride is a potent **cyclin-dependent kinase 2 (CDK2)** antagonist with an IC_{50} of 200 nM.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BML-259

Cat. No.: HY-108348

BML-259 is a potent cyclin-dependent kinase 5 **(Cdk5)** inhibitor, with IC_{50}s of 64 and 98 nM for Cdk5 and Cdk2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-265246

Cat. No.: HY-15275

BMS-265246 is a potent and selective CDK1/2 inhibitor for CDK1/cyclin B and CDK2/cyclin E with IC50 of 6 nM and 9 nM, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bohemine

Cat. No.: HY-12843

Bohemine is a purine analogue and is a synthetic and selective **CDK** inhibitor with IC_{50}s of 4.6 μM, 83 μM, and 2.7 μM for **Cdk2/cyclin E**, **Cdk2/cyclin A**, and **Cdk9/cyclin T1**, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Borrelidin

(Treponemycin)

Cat. No.: HY-N6742

Borrelidin (Treponemycin) is a bacterial and eukaryal **threonyl-tRNA synthetase** inhibitor which is a nitrile-containing macrolide antibiotic isolated from Streptomyces rochei. Borrelidin is an inhibitor of **Cdc28/Cln2** of the budding yeast, with an IC_{50} of 24 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

BRD6989

Cat. No.: HY-122586

BRD6989, an analog of the natural product cortistatin A (dCA), inhibits **CDK8** and upregulates **IL-10**. BRD6989 selectively binds a complex of CDK8 with an IC_{50} of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BS-181

Cat. No.: HY-13266

BS-181 is a potent and selective **CDK7** inhibitor (IC_{50}=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC_{50} values of 880, 3000 and 4200 nM, respectively (fails to block CDK1, 4 and 6).



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BS-181 dihydrochloride

Cat. No.: HY-110368

BS-181 dihydrochloride is a potent and selective **CDK7** inhibitor (IC_{50}=21 nM) than Seliciclib (HY-30237). BS-181 is also against CDK2, CDK5 and CDK9 with IC_{50} values of 880 nM, 3000 nM and 4200 nM, respectively (fails to block CDK1, 4 and 6).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BS-181 hydrochloride

Cat. No.: HY-13266A

BS-181 hydrochloride is a highly selective **CDK7** inhibitor with IC_{50} of 21 nM, and > 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BSJ-01-175

Cat. No.: HY-145072

BSJ-01-175 is a potent and selective **CDK12/13** covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BSJ-03-123

Cat. No.: HY-111556

BSJ-03-123 is a PROTAC connected by ligands for **Cereblon** and **CDK** as a potent and novel **CDK6**-selective small-molecule degrader.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BSJ-03-204

Cat. No.: HY-136250

BSJ-03-204 is a PROTAC connected by ligands for **Cereblon** and **CDK**. BSJ-03-204 is a potent and selective Palbociclib-based **CDK4/6** dual degrader (**PROTAC**), with IC_{50}s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BSJ-04-132

Cat. No.: HY-136252

BSJ-04-132 is a PROTAC connected by ligands for **Cereblon** and **CDK**. BSJ-04-132 is a potent and selective Ribociclib-based **CDK4** degrader (**PROTAC**), with IC_{50}s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 5 mg

BSJ-4-116

Cat. No.: HY-139039

BSJ-4-116 is a PROTAC connected by ligands for **Cereblon** and **CDK**. BSJ-4-116 is a highly potent and selective **CDK12** degrader (PROTAC) with an IC_{50} of 6 nM. BSJ-4-116 downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Butyrolactone I

(Olomoucin)

Cat. No.: HY-111237

Butyrolactone I is an ATP-competitive inhibitor of **CDK1** as a secondary metabolite from A. terreus. Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ca2+ channel agonist 1

Cat. No.: HY-41076

Ca^{2+} channel agonist 1 is an agonist of **N-type Ca^{2+} channel** and an inhibitor of **Cdk2**, with EC_{50}s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CA224

Cat. No.: HY-111207

CA224 (Compound 1) is a selective and orally active **Cdk4–cyclin D1** inhibitor with an IC_{50} of 6.2 μM. CA224 induces cell **apoptosis** and shows antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CAN508

Cat. No.: HY-100429

CAN508 is a potent, ATP-competitive **CDK9/cyclin T1** inhibitor with an IC_{50} of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Casein Kinase inhibitor A51

Cat. No.: HY-123954

Casein Kinase inhibitor A51 is a potent and orally active **casein kinase 1α (CK1α)** inhibitor. Casein Kinase inhibitor A51 induces leukemia cell **apoptosis**, and has potent anti-leukemic activities.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casein Kinase inhibitor A86

Cat. No.: HY-123955

Casein Kinase inhibitor A86 is a potent and orally active **casein kinase 1α (CK1α)** inhibitor. Casein Kinase inhibitor A86 also inhibits of **CDK7 (TFIIH)** and **CDK9 (P-TEFb)**. Casein Kinase inhibitor A861 induces leukemia cell **apoptosis**, and has potent anti-leukemic activities.



Purity: 98.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CC-671

Cat. No.: HY-108709

CC-671 is a dual **TTK protein kinase/CDC2-like kinase** (**CLK2**) inhibitor with IC_{50}s of 0.005 and 0.006 μM for TTK and CLK2, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT-251921

Cat. No.: HY-19984

CCT-251921 is a potent, selective, and orally bioavailable **CDK8** inhibitor with an IC_{50} of 2.3 nM.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cdc7-IN-1

Cat. No.: HY-101523

Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of **Cdc7 kinase**, with an IC_{50} value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics. Cdc7-IN-1 potently inhibits Cdc7 activity in cancer cells, and effectively induces cell death.



Purity: 99.30%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cdc7-IN-10

Cat. No.: HY-143381

Cdc7-IN-10 is a highly potent **Cdc7** inhibitor with IC_{50}≤1 nM. Cdc7-IN-10 can be used for researching proliferative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-11

Cat. No.: HY-143383

Cdc7-IN-11 is a highly potent **Cdc7** inhibitor with IC_{50}≤1 nM. Cdc7-IN-11 can be used for researching proliferative diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-17

Cat. No.: HY-143431

Cdc7-IN-17 is a potent **CDC7** inhibitor with an IC_{50} of <10 μM, extracted from patent WO2018217439A1. Cdc7-IN-17 can be used for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-3

Cat. No.: HY-130515

Cdc7-IN-3 (compound I-A) is a potent **Cdc7** kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-4

Cat. No.: HY-130516

Cdc7-IN-4 (compound I-C) is a potent **Cdc7** kinase inhibitor extracted from patent WO2019165473A1, compound I-C. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-5

Cat. No.: HY-130517

Cdc7-IN-5 (compound I-B) is a potent **Cdc7** kinase inhibitor extracted from patent WO2019165473A1, compound I-B. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.



Purity: 95.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cdc7-IN-7

Cat. No.: HY-130519

Cdc7-IN-7 (compound I-E) is a potent **Cdc7** kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdc7-IN-9

Cat. No.: HY-143380

Cdc7-IN-9 is a potent **Cdc7** inhibitor and can be used for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK-IN-2

(CDK inhibitor II)

Cat. No.: HY-13033

CDK-IN-2 is a potent and specific CDK9 inhibitor with IC50 of <8 nM, extracted from reference 1, example 4. IC50 Value: <8 nM Target: CDK9 In vitro: In vivo:.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

CDK-IN-6

Cat. No.: HY-78428

CDK-IN-6, a class of pyrazolo[1,5-a]pyrimidine compound, is a **CDK** inhibitor with anticancer activities.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg

CDK/HDAC-IN-1

Cat. No.: HY-132914

CDK/HDAC-IN-1 shows remarkable **CDK2/4/6** and **HDAC6** inhibitory activity of IC_{50} = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK1-IN-1

Cat. No.: HY-115924

CDK1-IN-7 is a potent **CDK1** inhibitor (CDK1/CycB IC_{50}=161.2 nM) with potential antiproliferative activity and selectivity for cancer tissues. CDK1-IN-7 induces **apoptosis** in p53 dependent manner through the intrinsic apoptotic pathway. CDK1-IN-7 is a potential targeted antitumor agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cdk1/2 Inhibitor III

Cat. No.: HY-112462

Cdk1/2 Inhibitor III is a selective **Cdk1/2** inhibitor, with an IC_{50} of 2.1 μM for CDK1/cyclin B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK12-IN-2

Cat. No.: HY-112626

CDK12-IN-2 is a potent, selective and nanomolar **CDK12** inhibitor (IC_{50}=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12.



Purity: 99.44%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDK12-IN-3

Cat. No.: HY-112261

CDK12-IN-3 is a potent and selective **CDK12** inhibitor with an IC_{50} of 491 nM in enzymatic assay.



Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDK12-IN-4

Cat. No.: HY-139327

CDK12-IN-4, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC_{50} of 0.641 μM at high ATP (2 mM). CDK12-IN-4 has no effect on CDK2/Cyclin E (IC_{50}>20 μM) and CDK9/Cyclin T1 (IC_{50}>20 μM) at high ATP (2 mM) (WO2021116178A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK12-IN-5

Cat. No.: HY-139328

CDK12-IN-5, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC_{50} of 23.9 nM at high ATP (2 mM). CDK12-IN-5 has no effect on CDK2/Cyclin E (IC_{50}=173 μM) and CDK9/Cyclin T1 (IC_{50}=127 μM) at high ATP (2 mM) (WO2021116178A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK12-IN-6

Cat. No.: HY-139329

CDK12-IN-6, a pyrazolotriazine, is a potent CDK12 inhibitor with an IC_{50} of 1.19 μM at high ATP (2 mM). CDK12-IN-6 has no effect on CDK2/Cyclin E (IC_{50}>20 μM) and CDK9/Cyclin T1 (IC_{50}>20 μM) at high ATP (2 mM) (WO2021116178A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CDK12-IN-E9

Cat. No.: HY-117203A

CDK12-IN-E9 is a potent and selective covalent **CDK12** inhibitor and a non-covalent **CDK9** inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC_{50}> 1 μM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDK2-IN-4

Cat. No.: HY-117535

CDK2-IN-4 is a potent and selective **CDK2** inhibitor with an IC_{50} of 44 nM for CDK2/cyclin A, shows 2,000-fold selectivity over CDK1/cyclin B (IC_{50}=86 uM).



Purity: 95.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CDK2-IN-7

Cat. No.: HY-139651

CDK2-IN-7 is a **CDK2** inhibitor for treating cancer (IC_{50} < 50 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4-IN-1-d6

Cat. No.: HY-15612S

CDK4-IN-1-d6 is a deuterium labeled CDK4-IN-1. CDK4-IN-1 (compound 63) is a CDK4 inhibitor (IC_{50}= 10 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CDK4/6-IN-10

Cat. No.: HY-115993

CDK4/6-IN-10 is a potent, selective and orally active **CDK4** and **CDK6** inhibitor with IC_{50}s of 22 nM and 10 nM, respectively. CDK4/6-IN-10 shows antitumor activity. CDK4/6-IN-10 has the potential for the research of Multiple myeloma (MM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6-IN-11

Cat. No.: HY-144995

CDK4/6-IN-11 is a potent **PROTAC CDK4/6** degrader.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6-IN-2

Cat. No.: HY-114339

CDK4/6-IN-2 is a potent **CDK4** and **CDK6** inhibitor extracted from patent US20180000819A1, Compound 1, has IC_{50}s of 2.7 and 16 nM for CDK4 and CDK6, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDK4/6-IN-3

Cat. No.: HY-126244

CDK4/6-IN-3 is a brain-penetrant **CDK4/CDK6** inhibitor with K_is of <0.3 nM and 2.2 nM, respectively. CDK4/6-IN-3 inhibits CDK1 with a K_i of 110 nM. CDK4/6-IN-3 can be used for the treatment of glioblastoma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6-IN-5

Cat. No.: HY-139449

CDK4/6-IN-5 is a potent **CDK4** and **CDK6** inhibitor with K_is of 0.2 and 4.4 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. (from patent WO2019207463A1 example A93).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6-IN-6

Cat. No.: HY-139450

CDK4/6-IN-6 (example A94) is a potent **CDK4/CDK6** inhibitor with a K_i of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6-IN-9

Cat. No.: HY-115992

CDK4/6-IN-9 (compound 10) is a selective **CDK4/6** inhibitor with an IC_{50} of 905 nM for CDK6/cyclin D1. CDK4/6-IN-9 has the potential for multiple myeloma (MM) research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK4/6/1 Inhibitor

Cat. No.: HY-112280

CDK4/6/1 Inhibitor is a **CDK4/6** inhibitor with IC_{50}s of 3 and 1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK5 inhibitor 20-223

Cat. No.: HY-123772

CDK5 inhibitor 20-223 is a potent **CDK2** and **CDK5** inhibitor with IC_{50}s of 6.0 and 8.8 nM, respectively. CDK5 inhibitor 20-223 is an effective anti-colorectal cancer (CRC) agent.



Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

CDK5-IN-1

Cat. No.: HY-139725

CDK5-IN-1, a potent **CDK5** inhibitor, is against CDK5 activity less than 10 nM. CDK5-IN-1 is used for kidney diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK5-IN-2

Cat. No.: HY-145693

CDK5-IN-2 (compound 15) is a highly selective **CDK5** inhibitor with IC_{50}s of 0.2 and 23 for CDK5/p25 and CDK2/CycA, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK5-IN-3

Cat. No.: HY-145694

CDK5-IN-3 (compound 11) is a potent and selective **CDK5** inhibitor, with IC_{50}s of 0.6 nM and 18 nM for **CDK5/p25** and **CDK2/CycA**, respectively. CDK5-IN-3 can be used for the research of autosomal dominant polycystic kidney disease (ADPKD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK6/9-IN-1

Cat. No.: HY-131063

CDK6/9-IN-1 (compound 66) is an orally active active and dual **CDK 6** and **CDK 9** inhibitor, with IC_{50} values of 40.5 nM and 39.5 nM for CDK6 anmd CDK9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK6/PIM1-IN-1

Cat. No.: HY-142696

CDK6/PIM1-IN-1 is a potent and balanced dual **CDK6/PIM1** inhibitor with IC_{50} values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC_{50}=3.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-1

Cat. No.: HY-101257A

CDK7-IN-1, an analog of YKL-5-124, is a **cyclin-dependent kinase 7** (**cdk7**) inhibitor, with an IC_{50} of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

CDK7-IN-10

Cat. No.: HY-145424

CDK7-IN-10 is a **CDK7** inhibitor with an IC_{50} of less than 100 nM, extracted from patent WO2021016388A1, compound I-1. CDK7-IN-10 is useful in inhibiting the activity of a kinase. CDK7-IN-10 has the potential of inhibiting cell growth and inducing cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-12

Cat. No.: HY-144175

CDK7-IN-12 is a potent inhibitor of **CDK7**. CDK7-IN-12 plays a key role in transcriptional regulation and cell cycle regulation. CDK7-IN-12 effectively inhibit malignant tumor proliferation in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-2

Cat. No.: HY-143587

CDK7-IN-2 is a potent inhibitor of **CDK7**. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII).



Purity: 98.93%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDK7-IN-2 hydrochloride hydrate

Cat. No.: HY-136711

CDK7-IN-2 hydrochloride hydrate (Example 6) is a potent and selective **CDK7** inhibitor. CDK7-IN-2 has potent anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-5

Cat. No.: HY-139986

CDK7-IN-5 is a **CDK7** inhibitor with an IC_{50} value <100 nM. CDK7-IN-5 has anticancer effects. (WO2015154022A1 (Compound 104)).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-6

Cat. No.: HY-145394

CDK7-IN-6 is a potent and selective cyclin-dependent kinase (**CDK7**) inhibitor (IC_{50}≤100 nM), extracted from patent WO2019197549 A1, compound 210. CDK7-IN-6 is > 200-fold selective for CDK7 over CDK1, CDK2, and CDK5. CDK7-IN-6 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-7

Cat. No.: HY-145402

CDK7-IN-7 is a potent and selective **CDK7 kinase** inhibitor with an IC_{50} of <50 nM (Patent CN112661745A, compound T-01).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7-IN-8

Cat. No.: HY-143586

CDK7-IN-8 is a potent **CDK7** inhibitor with IC_{50} of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7/12-IN-1

Cat. No.: HY-46568

CDK7/12-IN-1 is a selective **CDK7/12** inhibitor with IC_{50}s of 3 and 277 nM for CDK7 and CDK 12, respectively. CDK7 and CDK12 inhibition is an effective strategy to inhibit tumour growth.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK7/9 tide

Cat. No.: HY-P2559

CDK7/9 tide is peptide substrate for CDK7 or CDK9.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

CDK7/9-IN-1

Cat. No.: HY-145408

CDK7/9-IN-1 is a cyclin-dependent kinases 7/9 (**CDK7/9**) inhibitor. CDK7/9-IN-1 selectively inhibits CDK7 over CDK9. CDK7/9-IN-1 inhibits CDK7 with IC_{50}s of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK8-IN-1

Cat. No.: HY-103492

CDK8-IN-1 is a potent and selective **CDK8** inhibitor with an IC_{50} of 3 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CDK8-IN-3

Cat. No.: HY-111463

CDK8-IN-3 is an inhibitor of **CDK8** extracted from patent WO2016041618A1, compound example 1.7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK8-IN-4

Cat. No.: HY-111465

CDK8-IN-4 is an inhibitor of **CDK8** extracted from patent WO2014090692A1, compound example 16, with an IC_{50} of 0.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK8/19-IN-1

Cat. No.: HY-111427

CDK8/19-IN-1 is a potent, selective and oral bioavailable **CDK8/19** dual inhibitor, with IC_{50}s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-1

Cat. No.: HY-13231

CDK9-IN-1 is a novel, selective **CDK9** inhibitor for the treatment of HIV infection, with an IC_{50} of 39 nM for CDK9/CycT1, extracted from reference, compound 87.



Purity: 98.52
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CDK9-IN-10

Cat. No.: HY-130850

CDK9-IN-10 is a potent **CDK9** inhibitor. CDK9-IN-10 is the ligand for the PROTAC CDK9 degrader-2 (HY-112811).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-11

Cat. No.: HY-130852

CDK9-IN-11 is a potent **CDK9** inhibitor. CDK9-IN-11 is the ligand for the PROTAC CDK9 Degrader-1 (HY-103628).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-12

Cat. No.: HY-115714

CDK9-IN-12 displays the optimal **CDK9** inhibitory activity with an IC_{50} value of 5.41 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-13

Cat. No.: HY-139980

CDK9-IN-13 (compound 38) is potent and selective **CDK9** inhibitor, with an IC_{50} of <3 nM. CDK9-IN-13 exhibits short half-lives in rodents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-14

Cat. No.: HY-143585

CDK9-IN-14 is a potent and selective **CDK9** inhibitor with IC_{50} of 6.92 nM. CDK9-IN-14 has a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and has a good selectivity and a low toxicity and few side effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDK9-IN-2

Cat. No.: HY-16462

CDK9-IN-2 is a special cyclin-dependent kinase 9 (**CDK9**) inhibitor, extracted from patent WO/2012131594A1, compound CDKI(8), has an IC_{50} of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CDK9-IN-7

Cat. No.: HY-126251

CDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active **CDK9/cyclin T** inhibitor (IC_{50}=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CDK9-IN-8

Cat. No.: HY-102039

CDK9-IN-8 is a highly effective and selective **CDK9** inhibitor with an IC_{50} of 12 nM.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CDK9-IN-9

Cat. No.: HY-130001

CDK9-IN-9 (example 2) is a potent and selective **CDK9** inhibitor with an IC_{50} of 1.8 nM. CDK9-IN-9 inhibits CDK2 with an IC_{50} of 155 nM. CDK9-IN-9 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CDKI-73

(LS-007)

Cat. No.: HY-12445

CDKI-73 (LS-007) is an orally active and highly efficacious **CDK9** inhibitor, with K_i values of 4 nM, 4 nM and 3 nM for CDK9, CDK1 and CDK2, respectively. CDKI-73 down-regulates the RNAPII phosphorylation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CGP-82996

(CINK4)

Cat. No.: HY-136726

GP-82996 (CINK4) is a pharmacological inhibitor of **CDK4/6**. GP-82996 has IC_{50}s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the **apoptosis** of cancer cells U2OS. GP-82996 can be used in the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CGP60474

Cat. No.: HY-11009

CGP60474, a highly potent anti-endotoxemic agent, is a potent **cyclin-dependent kinase (CDK)** inhibitor (IC_{50} values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively).



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cimpuciclib

Cat. No.: HY-112243

Cimpuciclib is a **cyclin-dependent kinase(CDK)** inhibitor and antineoplastic.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cirtuvivint

(SM08502)

Cat. No.: HY-137435

Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CK7

Cat. No.: HY-103646

CK7, a **Cdk2/9** inhibitor, can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CKI-7

Cat. No.: HY-W011109

CKI-7 is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 is a selective **Cdc7 kinase** inhibitor. CKI-7 also inhibits **SGK**, **ribosomal S6 kinase-1 (S6K1)** and **mitogen- and stress-activated protein kinase-1 (MSK1)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CKI-7 free base

Cat. No.: HY-133028

CKI-7 free base is a potent and ATP-competitive **casein kinase 1 (CK1)** inhibitor with an IC_{50} of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective **Cdc7 kinase** inhibitor.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CLK-IN-T3

Cat. No.: HY-115470

CLK-IN-T3 is a high potent, selective, and stable **CDC-like kinase (CLK)** inhibitor with IC_{50}s of 0.67 nM, 15 nM, and 110 nM for CLK1, CLK2, and CLK3 protein kinases, respectively. CLK-IN-T3 has anti-cancer activity.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CLK-IN-T3N

Cat. No.: HY-130676

CLK-IN-T3N, the negative control of CLK-IN-T3 (HY-115470), is a chemical probe for **CDC-like kinase (CLK)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CLK1-IN-1

Cat. No.: HY-103082

CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (**CLK1**) inhibitor, with an IC_{50} of 2 nM.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CP-10

Cat. No.: HY-125835

CP-10 is a PROTAC connected by ligands for **Cereblon** and **CDK**, with highly selective, specific, and remarkable **CDK6** degradation (DC_{50}=2.1 nM).

Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CPS2

Cat. No.: HY-141680

CPS2 is a first-in-class, highly potent, selective and irreversible **PROTAC CDK2** degrader (IC_{50}= 24 nM). CPS2 can be used for the research of acute myeloid leukemia.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CTX-712

Cat. No.: HY-144875

CTX-712 is a potent inhibitor of cdc2-like kinase (**CLK**). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cucurbitacin E

(α-Elaterin; α-Elaterine)

Cat. No.: HY-N0417

Cucurbitacin E is a natural compound which from the climbing stem of Cucumic melo L. Cucurbitacin E significantly suppresses the activity of the **cyclin B1/CDC2** complex.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CVT-313

(Cdk2 Inhibitor III)

Cat. No.: HY-15339

CVT-313 (Cdk2 Inhibitor III) is a potent, selective, reversible, and ATP-competitive inhibitor of **CDK2** with IC_{50} of 0.5 μM. CVT-313 inhibits CDC5L phosphorylation.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Dalpiciclib

(SHR-6390)

Cat. No.: HY-114338

Dalpiciclib (SHR-6390) is a highly selective, orally bioavailable **CDK4/6** inhibitor with comparable potencies against CDK4 (IC_{50}=12.4nM) and CDK6 (IC_{50}=9.9nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dCeMM2

Cat. No.: HY-144971

dCeMM2 (Compound 2) is a glue degrader. dCeMM2 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

dCeMM3

Cat. No.: HY-144976

dCeMM3 (Compound 3) is a glue degrader. dCeMM3 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

dCeMM4

Cat. No.: HY-144977

dCeMM4 (Compound 5) is a glue degrader. dCeMM4 induces ubiquitination and degradation of cyclin K by prompting an interaction of CDK12-cyclin K with a CRL4B ligase complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DD-03-156

((S,R,S)-AHPC-Me-PEG2-dabrafenib)

Cat. No.: HY-137346

DD-03-156 is a potent and selective degrader of **CDK17** and **LIMK2**. The selectivity and potency of DD-03-156 is exquisite and makes an advanced starting point for the development of a chemical probe for the degradation of CDK17.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Desmethylglycitein

(4',6,7-Trihydroxyisoflavone)

Cat. No.: HY-N5072

Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dinaciclib

(SCH 727965)

Cat. No.: HY-10492

Dinaciclib (SCH 727965) is a potent inhibitor of **CDK**, with IC_{50}s of 1 nM, 1 nM, 3 nM, and 4 nM for **CDK2**, **CDK5**, **CDK1**, and **CDK9**, respectively.



Purity: 99.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DS96432529

Cat. No.: HY-145121

DS96432529 is a potent and orally active bone anabolic agent through **CDK8** inhibition.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Eciruciclib

Cat. No.: HY-145563

Eciruciclib is an antineoplastic and potent **cyclin dependent kinase (CDK)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-45

Cat. No.: HY-145867

EGFR-IN-45 is a potent epidermal growth factor receptor (**EGFR**) pan inhibitor, with IC_{50}s of 0.4 μM and 1.6 μM for **EGFR** and **CDK2**, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EHT 5372

Cat. No.: HY-111379

EHT 5372 is a highly potent and selective inhibitor of **DYRK's** family kinases with IC_{50}s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, 221 nM for **DYRK1A**, **DYRK1B** , DYRK2 DYRK3 CLK1, CLK2, CLK4, GSK-3α, GSK-3β.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fadraciclib

(CYC065) Cat. No.: HY-101212

Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of **CDK2/CDK9** kinases with IC_{50}s of 5 and 26 nM, respectively.



Purity: 99.78%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

FIT-039

Cat. No.: HY-18944

FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC_{50} of 5.8 μM for **CKD9/cyclin T1**. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of **HSV-1** (IC_{50} of 0.69 μM), **HSV-2**, **human adenovirus**, and **human CMV**.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Flavopiridol

(HMR-1275; Alvocidib; L86-8275) Cat. No.: HY-10005

Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of **CDKs**, inhibiting CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.



Purity: 99.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Flavopiridol Hydrochloride (Alvocidib Hydrochloride; L86-8275 Hydrochloride; HMR-1275 Hydrochloride)

Cat. No.: HY-10006

Flavopiridol Hydrochloride (Alvocidib Hydrochloride) is a broad inhibitor of **CDK**, competing with ATP to inhibit CDKs including CDK1, CDK2, CDK4 with IC_{50}s of 30, 170, 100 nM, respectively.



Purity: 98.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FLT3/CDK4-IN-1

Cat. No.: HY-115904

FLT3/CDK4-IN-1 is a potent, high selective and orally active **FLT3**/**CDK4** dual inhibitor (IC_{50}=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FMF-04-159-2

Cat. No.: HY-127104

FMF-04-159-2 is a covalent **CDK14** inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC_{50}s of 39.6 nM and 256 nM in NanoBRET assay, respectively.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FN-1501

Cat. No.: HY-111361

FN-1501 is a potent inhibitor of **FLT3** and **CDK**, with IC_{50}s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

FN-1501-propionic acid

Cat. No.: HY-130981

FN-1501-propionic acid is a **CDK2/9** ligand for PROTAC. FN-1501-propionic acid and a CRBN ligand have been used to design PROTAC CDK2/9 degrader (HY-130709).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Garcinone C

Cat. No.: HY-N6954

Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia Champ that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg

GFB-12811

Cat. No.: HY-144117

GFB-12811 is a high selective and orally active **CDK5** inhibitor with an IC_{50} of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK 3 Inhibitor IX

(6-Bromoindirubin-3'-oxime; BIO; MLS 2052) Cat. No.: HY-10580

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of **GSK-3α/β** and **CDK1-cyclinB** complex with IC_{50}s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.



Purity: 99.74%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GSK-3/CDK5/CDK2-IN-1

Cat. No.: HY-134622

GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of **cdk5**, **cdk2**, and **GSK-3** extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Haspin-IN-1

Cat. No.: HY-146586

Haspin-IN-1 (compound 2a) is a **haspin** inhibitor with an IC_{50} of 119 nM. Haspin-IN-1 also inbibits **CLK1** and **DYRK1A** with IC_{50}s of 221 nM and 916.3 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Haspin-IN-2

Cat. No.: HY-146587

Haspin-IN-2 (compound 4) is a potent and selective **haspin** inhibitor with an IC_{50} of 50 nM. Haspin-IN-1 also inbibits **CLK1** and **DYRK1A** with IC_{50}s of 445 nM and 917 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HDAC1/2 and CDK2-IN-1

Cat. No.: HY-143497

HDAC1/2 and CDK2-IN-1 (compound 14d) is a potent **HDAC1**, **HDAC2** and **CDK2** dual inhibitor, with IC_{50} values of 70.7, 23.1 and 0.80 μM, respectively. HDAC1/2 and CDK2-IN-1 can block the cell cycle and induce **apoptosis**. HDAC1/2 and CDK2-IN-1 exhibits desirable in vivo antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HQ461

Cat. No.: HY-144981

HQ461 is a **molecular glue** that promotes CDK12-DDB1 interaction to trigger **cyclin K** degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hSMG-1 inhibitor 11e

Cat. No.: HY-124760

hSMG-1 inhibitor 11e is a potent and selective **hSMG-1 kinase** inhibitor with an IC_{50} of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC_{50} of 45 nM), PI3Kα/γ (IC_{50}s of 61 nM and 92 nM) and CDK1/CDK2 (IC_{50}s of 32 μM and 7.1 μM).



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hSMG-1 inhibitor 11j

Cat. No.: HY-124719

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of **hSMG-1**, with an IC_{50} of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over **mTOR** (IC_{50}=50 nM), **PI3Kα/γ** (IC_{50}=92/60 nM) and **CDK1/CDK2** (IC_{50}=32/7.1 μM).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

IIIM-290

Cat. No.: HY-111356

IIIM-290 is a potent and oral **CDK** inhibitor with IC_{50}s of 90 and 94 nM for CDK2/A and CDK9/T1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Indirubin-3'-monoxime

(Indirubin-3'-oxime) Cat. No.: HY-19807

Indirubin-3'-monoxime is a potent **GSK-3β** inhibitor, and weakly inhibits **5-Lipoxygenase**, with IC_{50}s of 22 nM and 7.8-10 μM, respectively; Indirubin-3'-monoxime also shows inhibitory activities against CDK5/p25 and CDK1/cyclin B, with IC_{50}s of 100 and 180 nM.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Indirubin-3'-monoxime-5-sulphonic acid

Cat. No.: HY-111931

Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of **CDK1**, **CDK5**, and **GSK-3β** with IC_{50}s of 5 nM, 7 nM, and 80 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Indirubin-3'-oxime

(IDR3O; I3O)

Cat. No.: HY-139254

Indirubin-3'-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases **(CDKs)** and glycogen synthase kinase 3β **(GSK3β)**.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Indirubin-5-sulfonate

Cat. No.: HY-111932

Indirubin-5-sulfonate is a **cyclin-dependent kinase (CDK)** inhibitor, with IC_{50} values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against **GSK-3β**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ipivivint

Cat. No.: HY-137443

Ipivivint (compound 38) is a potent **CDC-like kinase (CLK)** inhibitor with EC_{50}s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits **Wnt** pathway (EC_{50}=13 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

IV-361

Cat. No.: HY-139011

IV-361 is an orally active and selective **CDK7** inhibitor (K_i≤50 nM). IV-361 has anti-cancer activity (US20190256531A1).



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JH-XI-10-02

Cat. No.: HY-111518

JH-XI-10-02 is a PROTAC connected by ligands for **Cereblon** and **CDK**. JH-XI-10-02 is a highly potent and selective **PROTAC CDK8** degrader, with an IC_{50} of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19.

Purity: 98.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

JH-XVI-178

Cat. No.: HY-139875

JH-XVI-178 is a highly potent and selective inhibitor of **CDK8/19** that displays low clearance and moderate oral pharmacokinetic properties.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-7706621

Cat. No.: HY-10329

JNJ-7706621 is a potent **aurora kinase** inhibitor, and also inhibits **CDK1** and **CDK2**, with IC_{50}s of 9 nM, 3 nM, 11 nM, and 15 nM for **CDK1**, **CDK2**, **aurora-A** and **aurora-B**, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

JSH-150

Cat. No.: HY-X0150

JSH-150 is a highly selective and potent **CDK9** inhibitor with an IC_{50} of 1 nM.



Purity: 98.36%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

K00546

Cat. No.: HY-103647

K00546 is a potent **CDK1** and **CDK2** inhibitor with IC_{50}s of 0.6 nM and 0.5 nM for **CDK1/cyclin B** and **CDK2/cyclin A**, respectively. K00546 is also a potent **CDC2-like kinase 1 (CLK1)** and **CLK3** inhibitor with IC_{50}s of 8.9 nM and 29.2 nM, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KB-0742 dihydrochloride

Cat. No.: HY-137478A

KB-0742 dihydrochloride is a potent, selective and orally active **CDK9** inhibitor with an IC_{50} of 6 nM for **CDK9/cyclin T1**. KB-0742 dihydrochloride is selective for **CDK9/cyclin T1** with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity.



Purity: 99.63%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Kenpaullone

(9-Bromopaullone; NSC-664704)

Cat. No.: HY-12302

Kenpaullone is a potent inhibitor of **CDK1/cyclin B** and **GSK-3β**, with IC_{50}s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC_{50}s of 0.68 μM, 7.5 μM, 0.85 μM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

KH-CB19

Cat. No.: HY-12828

KH-CB19 is a potent and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

KH-CB20

Cat. No.: HY-12828A

KH-CB20, an E/Z mixture, is a potent and selective inhibitor of **CLK1** and the closely related isoform **CLK4**, with an IC_{50} of 16.5 nM for **CLK1**. KH-CB20 can also inhibit **DYRK1A** (IC_{50}=57.8 nM) and **CLK3** (IC_{50}=488 nM).



Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

LDC000067

(LDC067)

Cat. No.: HY-15878

LDC000067 is a highly specific **CDK9** inhibitor with an IC_{50} value of 44±10 nM in vitro.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

LDC4297

Cat. No.: HY-12653

LDC4297 is a potent and selective **CDK7** inhibitor with an IC_{50} of 0.13 nM.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lerociclib

(G1T38)

Cat. No.: HY-112272

Lerociclib (G1T38) is a potent and selective inhibitor of **CDK4/6**, with IC_{50}s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Lerociclib dihydrochloride

(G1T38 dihydrochloride)

Cat. No.: HY-112272A

Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of **CDK4/CDK6**, with IC_{50}s of 1 nM and 2 nM for **CDK4/CyclinD1** and **CDK6/CyclinD3**, respectively.



Purity: 99.74%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Leucettine L41

Cat. No.: HY-117049

Leucettine L41 is a potent inhibitor of **dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), DYRK2, CDC-like kinase 1 (CLK1), and CLK3** (IC_{50}s = 0.04, 0.035, 0.015, and 4.5 μM, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Longdaysin

Cat. No.: HY-18285

Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits **CK1α**, **CK1δ**, **CDK7**, and **ERK2** with IC_{50}s of 5.6 μM, 8.8 μM, 29 μM, and 52 μM, respectively.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

LY2857785

Cat. No.: HY-12293

LY2857785 is a type I reversible and competitive ATP kinase inhibitor against **CDK9** (IC_{50} 11 nM) and other transcription kinases **CDK8** (IC_{50} 16 nM), and **CDK7** (IC_{50} 246 nM).



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

LY3177833

Cat. No.: HY-100023

LY3177833 is a **CDC7** and **pMCM2** inhibitor with IC_{50} values of 3.3 nM and 290 nM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

M2N12

Cat. No.: HY-128769

M2N12 is a potent and highly selective **cell division cycle 25C protein phosphatase (Cdc25C)** inhibitor with an IC_{50} value of 0.09 μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC_{50} values of 0.53 μM and 1.39 μM, respectively.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Manzamine A hydrochloride

Cat. No.: HY-117025A

Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically **GSK-3β** and **CDK-5** with IC_{50}s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets **vacuolar ATPases** and inhibits **autophagy** in pancreatic cancer cells.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MBQ-167

Cat. No.: HY-112842

MBQ-167 is a dual **Rac/Cdc42** inhibitor, with IC_{50}s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MC180295

((rel)-MC180295)

Cat. No.: HY-119940

MC180295 ((rel)-MC180295) is a potent and selective **CDK9-Cyclin T1** inhibitor, with an IC_{50} of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MeBIO

Cat. No.: HY-103221

MeBIO is a potent **AhR** (aryl hydrocarbon receptor) agonist, with IC_{50} of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively. MeBIO is inactive on GSK-3β.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mevociclib

(SY-1365)

Cat. No.: HY-128587

Mevociclib (SY-1365) is a potent and first-in-class selective **CDK7** inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines.



Purity: 99.27%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Milciclib

(PHA-848125)

Cat. No.: HY-10424

Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of **CDK** and **Tropomyosin receptor kinase (TRK)**, with IC_{50}s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ML167

(CID44968231; NCGC00188654)

Cat. No.: HY-15951

ML167 is a highly selective Cdc2-like kinase 4 (**Clk4**) inhibitor with IC_{50} of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

MSC2530818

Cat. No.: HY-101611

MSC2530818 is a potent, selective and orally available **CDK8** inhibitor with an IC_{50} of 2.6 nM for CDK8.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NCT02

Cat. No.: HY-W181530

NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NG 52

(Compound 52)

Cat. No.: HY-15154

NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active **Cdc28p** and **Pho85p kinase** inhibitor with IC_{50}s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of **phosphoglycerate kinase 1 (PGK1)** with an IC_{50} of 2.5 μM.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nimbolide

Cat. No.: HY-116035

Nimbolide is a triterpene derived from the leaves and flowers of neem (Azadirachta indica L). Nimbolide induces apoptosis through inactivation of **NF-κB**. Nimbolide inhibits **CDK4/CDK6** kinase activity. Nimbolide suppresses the NF-κB, Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 107512

Cat. No.: HY-141687

NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (**CDK9**). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces **apoptosis** of multiple myeloma tumors.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg

NSC 625987

Cat. No.: HY-103380

NSC 625987 is a specific and high-affinity **CDK4** inhibitor with an IC_{50} of 0.2 μM for **CDK4:cyclin D1**. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NSC693868

Cat. No.: HY-103381

NSC693868 is a selective inhibitor of **CDK1** and **CDK5** with IC_{50}**s** of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC_{50} of 1 μM) and does not block CDC25 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NU2058

(O6-(Cyclohexylmethyl)guanine)

Cat. No.: HY-19316

NU2058 (O6-(Cyclohexylmethyl)guanine) is a potent, competitive and guanine-based **CDK** inhibitor with IC_{50}s of 17 μM and 26 μM for CDK2 and CDK1. NU2058 has anti-cancer activity.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NU6027

Cat. No.: HY-13816

NU6027 is a potent and ATP-competitive inhibitor of both **CDK1** and **CDK2**, with K_is of 2.5 μM and 1.3 μM, respectively. NU6027 is also a potent inhibitor of **ATR** and enhances hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NU6102

Cat. No.: HY-15569

NU6102 is a potent **CDK1** and **CDK2** inhibitor with IC_{50}s of 9.5 nM and 5.4 nM for **CDK1/cyclinB** and **CDK2/cyclinA3**, respectively. NU6102 shows selectivity for **CDK1/CDK2** over CDK4 (IC_{50} of 1.6 μM), DYRK1A (IC_{50} of 0.9 μM), PDK1 (IC_{50} of 0.8 μM) and ROCKII (IC_{50} of 0.6 μM).



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg

NU6140

Cat. No.: HY-107419

NU6140 is a selective **CDK2-cyclin A** inhibitor (**IC_{50}**, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits **Aurora A** and **Aurora B**, with **IC_{50}**s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NU6300

Cat. No.: HY-18930

NU6300 is the first covalent, irreversible and ATP-competitive **CDK2** inhibitor.



Purity: 96.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-2

Cat. No.: HY-12214A

NVP-2 is a potent and selective ATP-competitive **cyclin dependent kinase 9 (CDK9)** probe, inhibits CDK9/CycT activity with an **IC_{50}** of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with **IC_{50}** values of 0.584 μM, 0.706 μM, and 0.605 μM, respectively.



Purity: 99.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-LCQ195

(LCQ-195; AT9311)

Cat. No.: HY-15241

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Olomoucine

Cat. No.: HY-W011428

Olomoucine is an ATP competitive inhibitor of **CDK**s. Olomoucine is a purine (HY-34431) derivative and inhibits CDC2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E (both **IC_{50}**=7 μM), CDK/p35 kinase (**IC_{50}**=3 μM) and ERK1/p44 MAP kinase (**IC_{50}**=25 μM).



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg

ON-013100

Cat. No.: HY-112822

ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit **Cyclin D1** expression.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ON123300

Cat. No.: HY-12624

ON123300, a strong and brain-penetrant multi-kinase inhibitor, inhibits **CDK4** (**IC_{50}**=3.9 nM), **Ark5** (**IC_{50}**=5 nM), **PDGFRβ** (**IC_{50}**=26 nM), **FGFR1** (**IC_{50}**=26 nM), **RET** (**IC_{50}**=9.2 nM), and **FYN** (**IC_{50}**=11 nM).



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

OTS964

Cat. No.: HY-19718

OTS964 is an orally active, high affinity and selective **TOPK** inhibitor with an **IC_{50}** of 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase **CDK11**, which binds to CDK11B with a **K_d** of 40 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OTS964 hydrochloride

Cat. No.: HY-12467

OTS964 hydrochloride is an orally active, high affinity and selective **TOPK** (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an **IC_{50}** of 28 nM.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Palbociclib

(PD 0332991)

Cat. No.: HY-50767

Palbociclib (PD 0332991) is a selective **CDK4** and **CDK6** inhibitor with **IC_{50}**s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.



Purity: 99.96%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Palbociclib isethionate

(PD 0332991 isethionate) Cat. No.: HY-A0065

Palbociclib isethionate is a highly selective inhibitor of **CDK4/6** with IC_{50}s of 11 nM/16 nM, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Palbociclib monohydrochloride

(PD 0332991 monohydrochloride) Cat. No.: HY-50767A

Palbociclib (PD 0332991) monohydrochloride is a highly selective **CDK4/6** inhibitor with IC_{50}s of 11 nM and 16 nM, respectively. Palbociclib monohydrochloride has the potential for ER-positive and HER2-negative breast cancer research.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Palbociclib-d4 hydrochloride

(PD 0332991-d4 hydrochloride) Cat. No.: HY-50767S1

Palbociclib-d4 (PD 0332991-d4) hydrochloride is the deuterium labeled Palbociclib hydrochloride. Palbociclib (PD 0332991) is a selective **CDK4** and **CDK6** inhibitor with IC_{50}s of 11 and 16 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palbociclib-d8

(PD 0332991-d8) Cat. No.: HY-50767S

Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active **CDK4** and **CDK6** inhibitor with IC_{50}s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 1 mg

PF 477736

(PF 00477736) Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PHA-767491

(CAY10572) Cat. No.: HY-13461

PHA-767491 is a dual **Cdc7/Cdk9** inhibitor, with IC_{50}s of 10 nM and 34 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHA-767491 hydrochloride

(CAY-10572 hydrochloride) Cat. No.: HY-13461A

PHA-767491 hydrochloride is a dual **Cdc7/Cdk9** inhibitor, with IC_{50}s of 10 nM and 34 nM, respectively.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PHA-793887

Cat. No.: HY-11001

PHA-793887 is a potent, ATP-competitive **CDK** inhibitor, can inhibit Cdk2, Cdk1, Cdk4, and Cdk9 with IC_{50}s of 8 nM, 60 nM, 62 nM and 138 nM, respectively, and also inhibits glycogen synthase kinase 3β with an IC_{50} of 79 nM.



Purity: 99.25%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PNU112455A hydrochloride

Cat. No.: HY-112468

PNU112455A hydrochloride is an ATP-competitive **CDK2** and **CDK5** inhibitor. PNU112455A hydrochloride binds to the ATP site of CDK2 and CDK5 with K_ms of 3.6 and 3.2 μM, respectively.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PROTAC CDK2/9 Degrader-1

Cat. No.: HY-130709

PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for **CDK2** (DC_{50}=62 nM) and **CDK9** (DC_{50}=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC_{50}=0.12 μM) by effectively blocking the cell cycle in S and G2/M phases.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PROTAC CDK9 Degrader-1

Cat. No.: HY-103628

PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for **Cereblon** and **CDK** as a selective **CDK9** degrader.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC CDK9 degrader-2

Cat. No.: HY-112811

PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective **CDK9** degrader based on **PROTAC**, with an IC_{50} of 17 μM in MCF-7 cell lines. Natural product Wogonin (**CDK** ligand) binds ubiquitin E3 ligase **Cereblon** (CRBN) via a linker to form PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Purvalanol A

(NG-60)

Cat. No.: HY-18299A

Purvalanol A is a potent **CDK** inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC_{50}s of 4, 70, 35, 850, 75 nM, resepctively.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Purvalanol B

(NG 95)

Cat. No.: HY-18299

Purvalanol B (NG 95) is a potent, selective, reversible and ATP-competitive inhibitor **CDK**, with IC_{50}s of 6 nM, 6 nM, 9 nM, 6 nM for **cdc2-cyclin B**, **CDK2-cyclin A**, **CDK2-cyclin E** and **CDK5-p35**, respectively.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

R547

Cat. No.: HY-10014

R547 is a potent, selective and orally active ATP-competitive **CDK** inhibitor, with K_is of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.07%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib

(LEE011)

Cat. No.: HY-15777

Ribociclib (LEE01) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib hydrochloride

(LEE011 hydrochloride)

Cat. No.: HY-15777A

Ribociclib hydrochloride (LEE011 hydrochloride) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib succinate

(LEE011 succinate)

Cat. No.: HY-15777B

Ribociclib succinate (LEE011 succinate) is a highly specific **CDK4/6** inhibitor with IC_{50} values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.52%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ribociclib succinate hydrate

(LEE011 succinate hydrate) Cat. No.: HY-15777C

Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific **CDK4/6** inhibitor with **IC_{50}** values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ribociclib-d6

(LEE011-d6) Cat. No.: HY-15777S

Ribociclib D6 (LEE011 D6) is a deuterium labeled Ribociclib. Ribociclib is a highly specific **CDK4/6** inhibitor with **IC_{50}** values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Ribociclib-d6 hydrochloride

(LEE011-d6 hydrochloride) Cat. No.: HY-15777AS

Ribociclib D6 (LEE011 D6) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific **CDK4/6** inhibitor with **IC_{50}** values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.



Purity: 98.37%
Clinical Data: No Development Reported
Size: 5 mg

Rintodestrant

(G1T48) Cat. No.: HY-137449

Rintodestrant (G1T48) is an orally active, non-steroidal and selective **estrogen receptor** degrader. Rintodestrant (G1T48) is also a **CDK4/6** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Riviciclib

(P276-00 free base) Cat. No.: HY-16559A

Riviciclib (P276-00 free base) is a potent **cyclin-dependent kinase (CDK)** inhibitor, which inhibits **CDK9-cyclinT1**, **CDK4-cyclin D1**, and **CDK1-cyclinB** with **IC_{50}**s of 20 nM, 63 nM, and 79 nM, respectively. Riviciclib shows antitumor activity on cisplatin-resistant cells.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Riviciclib hydrochloride

(P276-00) Cat. No.: HY-16559

Riviciclib hydrochloride (P276-00) is a potent **cyclin-dependent kinase (CDK)** inhibitor, which inhibits **CDK9-cyclinT1**, **CDK4-cyclin D1**, and **CDK1-cyclinB** with **IC_{50}**s of 20 nM, 63 nM, and 79 nM, respectively.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ro-3306

Cat. No.: HY-12529

Ro-3306 is a potent and selective inhibitor of **CDK1**, with **K_i**s of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Roniciclib

(BAY 1000394) Cat. No.: HY-13914

Roniciclib is an orally bioavailable pan-cyclin dependent kinase **(CDK)** inhibitor, with **IC_{50}s** of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ryuvidine

Cat. No.: HY-100624

Ryuvidine is a potent inhibitor of **SET domain-containing protein 8(SETD8)** with an **IC_{50}** of 0.5 μM and suppresses monomethylation of **H_4K_{20}** in vitro. Ryuvidine also inhibits **CDK4** with an **IC_{50}** of 6.0 μM and is cytotoxic against a range of human cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Samuraciclib

(CT7001; ICEC0942) Cat. No.: HY-103712

Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active **CDK7** inhibitor, with an **IC_{50}** of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC_{50} of 578 nM), CDK5 and CDK9, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Samuraciclib hydrochloride

(CT7001 hydrochloride; ICEC0942 hydrochloride) Cat. No.: HY-103712A

Samuraciclib hydrochloride (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active **CDK7** inhibitor, with an IC_{50} of 41 nM. Samuraciclib hydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC_{50} of 578 nM), CDK5 and CDK9, respectively.



Purity: 99.98%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Samuraciclib hydrochloride hydrate (CT7001 hydrochloride hydrate; ICEC0942 hydrochloride hydrate)

Cat. No.: HY-103712B

Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active **CDK7** inhibitor, with an IC_{50} of 41 nM.



Purity: 99.08%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SB-218078

Cat. No.: HY-107407

SB-218078 is a potent, selective, ATP-competitive and cell-permeable **checkpoint kinase 1 (Chk1)** inhibitor that inhibits **Chk1** phosphorylation of cdc25C with an IC_{50} of 15 nM. SB-218078 is less potently inhibits **Cdc2** (IC_{50} of 250 nM) and **PKC** (IC_{50} of 1000 nM).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SEL120-34A

Cat. No.: HY-111388

SEL120-34A is a potent, selective, orally available, ATP-competitive **CDK8** inhibitor, with IC_{50}s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SEL120-34A HCl

Cat. No.: HY-111388B

SEL120-34A HCl is a potent, selective, orally available, ATP-competitive **CDK8** inhibitor, with IC_{50}s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SEL120-34A monohydrochloride

Cat. No.: HY-111388A

SEL120-34A monohydrochloride is an ATP-competitive and selective **CDK8** inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC_{50}s of 4.4 nM and 10.4 nM, respectively, with a K_d of 3 nM for CDK8.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Seliciclib

(Roscovitine; CYC202; R-roscovitine) Cat. No.: HY-30237

Seliciclib (Roscovitine) is an orally bioavailable and selective **CDKs** inhibitor with IC_{50}s of 0.2 μM, 0.65 μM, and 0.7 μM for **CDK5**, **Cdc2**, and **CDK2**, respectively.



Purity: 98.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Senexin A

Cat. No.: HY-15681

Senexin A is a **CDK8** inhibitor with an IC_{50} of 280 nM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Simurosertib

(TAK-931) Cat. No.: HY-100888

Simurosertib (TAK-931) is an orally active, selective and ATP-competitive **cell division cycle 7 (CDC7)** kinase inhibitor, with an IC_{50} of <0.3 nM. Simurosertib has anti-cancer activity.



Purity: 99.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

SNS-032

(BMS-387032) Cat. No.: HY-10008

SNS-032 (BMS-387032) is a potent and selective inhibitor of **CDK2**, **CDK7**, and **CDK9** with IC_{50}s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect.



Purity: 99.49%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SR-4835

Cat. No.: HY-130250

SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of **CDK12/CDK13** (CDK12: IC_{50}=99 nM, K_d=98 nM; CDK13: K_d=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SRI-29329

Cat. No.: HY-123600

SRI-29329 is a specific **CLK** inhibitor, with IC_{50} values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

SU9516

Cat. No.: HY-18629

SU9516 is a potent **CDK2** inhibitor, with an IC_{50} of 22 nM, and also shows inhibitory effects on CDK1 and CDK4, with IC_{50}s of 40, 200 nM, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SY-5609

(CDK7-IN-3)

Cat. No.: HY-138293

SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent **CDK7** inhibitor with a K_D of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (K_i=2600 nM), CDK9 (K_i=960 nM), CDK12 (K_i=870 nM). SY-5609 induces **apoptosis** in tumor cells and has antitumor activity.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SZ-015268

Cat. No.: HY-145389

SZ-015268 is a **CDK7** inhibitor with an IC_{50} of 23.56 nM. SZ-015268 has extremely significant anti-tumor advantages. SZ-015268 inhibits HCC70, OVCAR-3, HCT116 and HCC1806 cells proliferation with IC_{50}s of 33, 80.56, 12.53, and 61.55 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

T025

Cat. No.: HY-112296

T025 is an orally available and highly potent **Cdc2-like kinase (CLK)** inhibitor with K_ds of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, respectively.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tanuxiciclib

Cat. No.: HY-145599

Tanuxiciclib is a **cyclin dependent kinase (CDK)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TC11

Cat. No.: HY-129478

TC11 is a **MCL1** degrader. TC11 is also a **Caspase-9** and **CDK1** activator. TC11 structurally relates to immunomodulatory drugs as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of **MCL1** during prolonged mitotic arrest.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TG003

Cat. No.: HY-15338

TG003 is a potent inhibitor of **Clk1/Sty**; inhibits Clk1 and Clk4 with IC_{50} values of 20 and 15 nM, respectively.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

THAL-SNS-032

Cat. No.: HY-123937

THAL-SNS-032 is a selective **CDK9** degrader PROTAC consisting of a **CDK**-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase **Cereblon** (CRBN).



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg

THZ1

Cat. No.: HY-80013

THZ1 is a selective and potent covalent **CDK7** inhibitor with an IC_{50} of 3.2 nM. THZ1 also inhibits the closely related kinases **CDK12** and **CDK13** and downregulates MYC expression.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ1 Hydrochloride

Cat. No.: HY-80013A

THZ1 Hydrochloride is a selective and potent covalent **CDK7** inhibitor with an IC_{50} of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases **CDK12** and **CDK13** and downregulates MYC expression.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ1-R

Cat. No.: HY-19988

THZ1-R is a non-cysteine reactive analog of THZ1 which displays diminished activity for **CDK7** inhibition. THZ1-R binds to **CDK7** with a K_d of 142 nM.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

THZ2

Cat. No.: HY-12280

THZ2 is a potent and selective **CDK7** inhibitor with an IC_{50} of 13.9 nM.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

THZ531

Cat. No.: HY-103618

THZ531 is a selective and covalent inhibitor of both **CDK12** and **CDK13** with IC_{50}s of 158 nM and 69 nM, respectively.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

TL12-186

Cat. No.: HY-130665

TL12-186 is a **Cereblon**-dependent multi-kinase **PROTAC** degrader. Multi-kinases include **CDK**, **BTK**, **FLT3**, **Aurora kinases**, **TEC**, **ULK**, **ITK**, et al. TL12-186 inhibits **CDK2/cyclin A** (IC_{50}=73 nM) and **CDK9/cyclin T1** (IC_{50}=55 nM).

Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Trilaciclib

(G1T28)

Cat. No.: HY-101467

Trilaciclib is a **CDK4/6** inhibitor with IC_{50}s of 1 nM and 4 nM for CDK4 and CDK6, respectively.



Purity: 99.20%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

Trilaciclib hydrochloride

(G1T28 hydrochloride)

Cat. No.: HY-101467A

Trilaciclib hydrochloride (G1T28 hydrochloride) is a **CDK4/6** inhibitor with IC_{50}s of 1 nM and 4 nM for CDK4 and CDK6, respectively.



Purity: 99.24%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

Voruciclib

Cat. No.: HY-12422

Voruciclib is an orally active and selective **CDK** inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib potently blocks CDK9, the transcriptional regulator of MCL-1. Voruciclib represses expression of MCL-1 in multiple models of diffuse large B-cell lymphoma (DLBCL).



Purity: 99.52%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Voruciclib hydrochloride

Cat. No.: HY-12422A

Voruciclib hydrochloride is an orally active and selective **CDK** inhibitor with K_i values of 0.626 nM-9.1 nM. Voruciclib hydrochloride potently blocks CDK9, the transcriptional regulator of MCL-1.



Purity: 98.20%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Wogonin

Cat. No.: HY-N0400

Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of **CDK8** and **Wnt**, and exhibits anti-inflammatory and anti-tumor effects.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

XL413

Cat. No.: HY-15260

XL413 is a potent, selective and ATP competitive inhibitor of **Cdc7**, with an IC_{50} of 3.4 nM, and also shows potent effect with IC_{50}s of 215, 42 nM on CK2, PIM1, respectively, and an EC_{50} of 118 nM on pMCM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XL413 hydrochloride

(BMS-863233 hydrochloride)

Cat. No.: HY-15260A

XL413 (BMS-863233) hydrochloride is a potent, selective and ATP competitive inhibitor of **Cdc7**, with an IC_{50} of 3.4 nM, and also shows potent effect with IC_{50}s of 215, 42 nM on CK2, PIM1, respectively, and an EC_{50} of 118 nM on pMCM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

XY028-133

Cat. No.: HY-129180

XY028-133 (example 14) is a **PROTAC**-based **CDK4/6** degrader with anti-tumor activity, which consists of ligands for **von Hippel-Lindau** and **CDK**.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XY028-140

Cat. No.: HY-138946

XY028-140 is a PROTAC connected by ligands for **Cereblon** and **CDK**. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells.



Purity: 98.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

YKL-5-124

Cat. No.: HY-101257

YKL-5-124 is a potent, selective, irreversible and covalent **CDK7** inhibitor with IC_{50}s of 53.5 nM and 9.7 nM for **CDK7** and **CDK7/Mat1/CycH**, respectively. YKL-5-124 is >100-fold greater selective for **CDK7** than CDK9 and CDK2, and inactive against CDK12 and CDK13.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

YKL-5-124 TFA

Cat. No.: HY-101257B

YKL-5-124 TFA is a potent, selective, irreversible and covalent **CDK7** inhibitor with IC_{50}s of 53.5 nM and 9.7 nM for **CDK7** and **CDK7/Mat1/CycH**, respectively. YKL-5-124 TFA is >100-fold greater selective for **CDK7** than CDK9 and CDK2, and inactive against CDK12 and CDK13.



Purity: 98.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ZDLD13

Cat. No.: HY-115908

ZDLD13, a β-carboline, is an orally active and selective **CDK4/CycD3** inhibitor with an IC_{50} value of 0.38 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZDLD20

Cat. No.: HY-115909

ZDLD20, a β-carboline, is orally active and selective **CDK4/CycD3** inhibitor with an IC_{50} value of 6.51 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[pSer2, pSer5, pSer7]-CTD TFA

Cat. No.: HY-P1933A

[pSer2, pSer5, pSer7]-CTD (TFA), a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[pThr3]-CDK5 Substrate

Cat. No.: HY-P1906

[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

[pThr3]-CDK5 Substrate TFA

Cat. No.: HY-P1906A

[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is derived from the sequence of the histone H1 peptide that docks in the active site of CDK5. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a K_m value of 6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg